Cost-effectieness of ceftriaxone 1 g s second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany

Infection

Volumn 27, Issue 2, 1999, Pages 148-154

  Dietrich, E S ^a,f   Joseph, U ^b   Ogel, F ^c   Ho, S ^d   Kulimann, K H ^e   Frank, U ^f   Daschner, F D ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c Medizinische Poliklinik   (Germany)

^d Krankenhaus Hofheim Taunus   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; GERMANY; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CEFTRIAXONE; CEPHALOSPORINS; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 0033087418     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02560518     Document Type: Article

References (19)

1. Schulenburg, J. M., Uber, A.: Current issues in German health care.Pharmacoeconomics 12 (1997) 517-523.
2. Schmitz, W.: Antibiotika und Chemotherapeutika. In: Schwabe, U., Paffratli, D. (eds): Arzneierordnungs-Report '95. Aktuelle Daten, Kosten, Trends und Kommentare.Gusta. Rscher . Ann. Hematol. 64 erlag, Stuttgart 1995, pp. 57-71.
3. American Thoracic Society: Hospital-acquired pneumonia in adults: diagnosis, assessment of seerity, initial antimicrobial therapy, and preentie strategies. Am. J. Respir. Crit. Care Med. 153 (1995) 1711-1725.
4. Huchon, G., Woodhead, M., Gialdroni-Grassi; G., Léophonte, P., Manresa, F., Schaberg, T., Torres, A., Didier, A., Dorca, J., El Ebiary, M., Roche, N.: Guidelines for management of adult communityacquired lower respiratory tract infections. Eur. Respir. J. 11 (1998) 986-991.
5. Paul-Ehrlich-Gescllschaft: Cephalosporine zur parenteralen Applikation - Konsensuskonferenz der Paul-Ehrlich-Gesellschaft für Chemotherapie.Hematol. Chemotherapie Journal 3 (1994) 101-115.
6. Low, D. E., Mandell, L. A.: A prospectie open-label multicentre trial on the use of 1 g, once daily ceftriaxone in lower respiratory tract infections. Can. J. Infect. Dis. 5 (Suppl. C) (1994) 3C-8C.
7. Focht, J., Nösner, K.: Empfindlichkeitsspektrum on Ceftriaxon und anderen Antibiotika. Krankenhauspharmazie 11 (1997) 531-534.
8. Sege, S., Raz, R., Rubinsfein, E., Shmuery, H., Hassin, D., Rosen, N., Platau, E., Ben Assuli, S., Pitlik, S.: Double-blind randomized study of 1 g ersus 2 g intraenous ceftriaxone daily in the therapy of community-acquired infections. Eur. J. Clin. Microbiol. Infect. Dis. 14(1995)851-855.
9. Gesellschaft für Pharmainformationssysteme: GPI Krankenhausindex 2. Quartal 1996. Frankfurt 1996.
10. Strehl, E., Brennscheidt, U., Mülder, P.:Antibiotikatherapie schwerer Infektionen. Krankenhauspharmazie 8 (1995) 330-335.
11. Paradis, D.,Allard, F., Allard, S., Bisson, C., Daiau, N., Drapeau, D., Auger, F., LeBel, M.: Comparati Hematolities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin. Antimicrob. Agents Chemother.36 (1992) 2085-2092.
12. Adu, A., Armour, C. L.: Drug utilisation reiew (DUR) of the third generation cephalosporins. Drugs50 (1995) 423-439.
13. Beringcr, P. M., Wong-Beringer, A., Rho, J. P.: Economic aspects of antibacterial ad.Pharmacoeconomics 13 (1998) 35-49.
14. Niebuhr, H., Nahrsledl, U., Riickert, K., Kaiser, W., Mosebach, B., Hoffmann, P., Schlote, F.; Lauenroth-Mai, E., Schuhknccht, R., Justiz, R., Kracht, T., Meeth, A., Forycki, F., Lode, H., Frommelt, L., Langmaack, H.: Empirische Therapie der nosokomialen oder ambulant erworbenen bakteriellen Pneumonie. Chemotherapie Journal 1 (1993) 28-35.
15. Capri, S., Dellamano, R.: Cost-effectieness in the hospital use of antibiotics: introductory considerations. J. Chemother.5 (1993) 348-351.
16. Capri, S., Carella, E., Catena, E.: alutazione clinica ad economica della terapia delle infezioni acute delle basse ie respiratorie con cefalosporine di terza generazione.Farmacia e Terapia 10 (1993) 27-35.
17. Mangi, K., Peccerillo, K. M., Ryan, J., Berenson, C., Greco, T., Thornton, G., Andriole, . T.: Cefoperazone ersus ceftriaxone monotherapy of nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 15 (1992) 441-447.
18. Gotfried, M. H., Killian, A. D., Seri, R. J., Danziger, L. H., Rodold, K. A.: I. cefuroxime plus oral clarithromycin or i. erythromycin for the treatment of community-acquired pneumonia in hospitalised, patients. Clin. Drug Inest. 14 (1997) 23-34.
19. Federal Statistical Office: Statistisches Jahrbuch 1997. MetzlerPoeschel, Stuttgart 1997, pp. 449.